461 results on '"Ylikorkala, Olavi"'
Search Results
2. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy
3. Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse
4. Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled trial of postmenopausal hormone therapy
5. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland
6. Effect of hot flushes on cardiovascular autonomic responsiveness: A randomized controlled trial on hormone therapy
7. Cardiovascular autonomic responsiveness in postmenopausal women with and without hot flushes
8. Use of estradiol–progestin therapy associates with increased risk for uterine sarcomas
9. Vaginal estradiol use and the risk for cardiovascular mortality
10. Postmenopausal hormone therapy–also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma
11. Postmenopausal hot flushes and bone mineral density: a longitudinal study
12. Coronary Heart Disease Mortality and Hormone Therapy Before and After the Womenʼs Health Initiative
13. Soy–tibolone combination—Effect on lipids in postmenopausal monkeys and women
14. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation
15. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
16. Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy
17. Benefits and risks of long-term low-dose oral continuous combined hormone therapy
18. Adiponectin Concentrations in Maternal Serum: Elevated in Preeclampsia But Unrelated to Insulin Sensitivity
19. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer—A population-based case control study from Finland
20. Smoking is accompanied by a suppressed cervical nitric oxide release in women with high-risk human papillomavirus infection
21. Decreasing perinatal mortality in placental abruption
22. Postmenopausal estradiol–progestagen therapy and risk for uterine cervical cancer
23. A Nationwide Cohort Study on the Incidence of Meningioma in Women Using Postmenopausal Hormone Therapy in Finland
24. Cervical nitric oxide release in Chlamydia trachomatis and high-risk human papillomavirus infection
25. Cervical nitric oxide release and persistence of high-risk human papillomavirus in women
26. Endometrial cancer associated with various forms of postmenopausal hormone therapy: A case control study
27. Self-reported smoking habits and serum cotinine levels in women with placental abruption
28. Endometriosis and assisted reproduction techniques
29. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: National-wide case-control study from Finland
30. Male fetal sex is associated with earlier onset of placental abruption
31. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well
32. Maternal Serum Angiopoietin-1 and -2 and Tie-2 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
33. Effect of Hot Flushes on Vascular Function: A Randomized Controlled Trial
34. Maternal deaths in Finland: Focus on placental abruption
35. Maternal serum endostatin at gestational weeks 16–20 is elevated in subsequent pre-eclampsia but not in intrauterine growth retardation
36. Abnormal cervical cytology is associated with increased nitric oxide release in the uterine cervix
37. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women
38. Misoprostol induces cervical nitric oxide release in pregnant, but not in nonpregnant, women
39. Culturing of human vascular endothelial cells strongly affects their endothelin-1 and prostacyclin production
40. Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption
41. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption
42. Maternal origin of nucleated erythrocytes in peripheral venous blood of pregnant women
43. Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy
44. Clinical presentation and risk factors of placental abruption
45. Maternal Serum-Soluble Vascular Endothelial Growth Factor Receptor-1 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
46. Prepregnancy risk factors for placental abruption
47. Is there any link between insulin resistance and inflammation in established preeclampsia?
48. Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy
49. Changes in bone mineral density during and after 3 years’ use of tamoxifen or toremifene
50. HRT as secondary prevention of cardiovascular disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.